Premium
Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: A real life survey
Author(s) -
BÜYÜKÖZTÜRK Suna,
GELINCIK Aslı,
DEMIRTÜRK Mustafa,
KOCATURK Emek,
ÇOLAKOĞLU Bahattin,
DAL Murat
Publication year - 2012
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2011.01473.x
Subject(s) - omalizumab , medicine , angioedema , chronic urticaria , quality of life (healthcare) , hereditary angioedema , adverse effect , first line , dermatology , asthma , dermatology life quality index , immunoglobulin e , immunology , disease , antibody , nursing
Treatment of chronic urticaria consists of antihistamines as the first‐line treatment. For more severe symptoms, combinations can be necessary as well as dose augmentations. The recent guidelines suggest the possibility of using omalizumab in resistant cases, but this therapy is still investigational. We treated two patients with idiopathic recurrent angioedema and 12 patients with chronic spontaneous urticaria (CSU) with omalizumab, who had not benefited from the recommended first‐line, second‐line and third‐line treatments. To evaluate the efficacy of the omalizumab treatment, urticaria activity scores (UAS) and chronic urticaria quality of life (CU‐Q2oL) scores were measured at baseline, and at the end of the first and sixth month of the therapy. The dosage and intervals of omalizumab therapy were determined according to the rules suggested for severe asthma treatment. CU‐Q2oL scores and UAS displayed significant improvements in all 14 patients. None of the patients reported any adverse effect during the treatment until the submission of this data. Our results show that omalizumab apparently improves CU‐Q2oL as well as UAS in treatment‐resistant CSU in a real life setting.